To date, molecularly targeted therapeutics, such as multitargeted receptor tyrosine kinase (RTK) or mammalian target of rapamycin (mTOR) inhibitors, and anti-programmed death-1 (PD-1) antibodies have been widely used for patients with metastatic or recurrent RCC. Here, MTOR is linked to renal cell carcinoma.